Programmed cell death-1 inhibition in lymphoma

Ferlay, 2015, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 Jaffe, 2001 Coiffier, 2010, Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte, Blood, 116, 2040, 10.1182/blood-2010-03-276246 Batlevi, 2013, Novel therapy for Hodgkin lymphoma, Hematology, 2013, 394, 10.1182/asheducation-2013.1.394 Fowler, 2013, Targeting B-cell receptor signaling: changing the paradigm, 2013, 553 Hernandez-Ilizaliturri, 2011, Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype, Cancer, 117, 5058, 10.1002/cncr.26135 Dunleavy, 2009, Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma, Blood, 113, 6069, 10.1182/blood-2009-01-199679 Quezada, 2013, Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer, Br J Cancer, 108, 1560, 10.1038/bjc.2013.117 Zou, 2008, Inhibitory B7-family molecules in the tumour microenvironment, Nat Rev Immunol, 8, 467, 10.1038/nri2326 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331 Latchman, 2001, PD-L2 is a second ligand for PD–1 and inhibits T cell activation, Nat Immunol, 2, 261, 10.1038/85330 Yamamoto, 2008, PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma, Blood, 111, 3220, 10.1182/blood-2007-05-085159 Blank, 2004, PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells, Cancer Res, 64, 1140, 10.1158/0008-5472.CAN-03-3259 Norris, 2012, PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection, Vir Immunol, 25, 329, 10.1089/vim.2011.0096 Okazaki, 2001, PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine, Proc Natl Acad Sci USA, 98, 13866, 10.1073/pnas.231486598 Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm0902-1039c Ghebeh, 2006, The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, 8, 190, 10.1593/neo.05733 Thompson, 2007, Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy, Clin Cancer Res, 13, 709, 10.1158/1078-0432.CCR-06-1868 Nomi, 2007, Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer, Clin Cancer Res, 13, 2151, 10.1158/1078-0432.CCR-06-2746 Wu, 2006, Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance, Acta Histochem, 108, 19, 10.1016/j.acthis.2006.01.003 Hamanishi, 2007, Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer, Proc Natl Acad Sci USA, 104, 3360, 10.1073/pnas.0611533104 Hino, 2010, Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer, 116, 1757, 10.1002/cncr.24899 Myklebust, 2013, High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells, Blood, 121, 1367, 10.1182/blood-2012-04-421826 Andorsky, 2011, Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells, Clin Cancer Res, 17, 4232, 10.1158/1078-0432.CCR-10-2660 Rossille, 2014, High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial, Leukemia, 28, 2367, 10.1038/leu.2014.137 Xerri, 2008, Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia, Hum Pathol, 39, 1050, 10.1016/j.humpath.2007.11.012 Chen, 2013, PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies, Clin Cancer Res, 19, 3462, 10.1158/1078-0432.CCR-13-0855 Hirano, 2005, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity, Cancer Res, 65, 1089, 10.1158/0008-5472.1089.65.3 Iwai, 2005, PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells, Int Immunol, 17, 133, 10.1093/intimm/dxh194 Curiel, 2003, Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity, Nat Med, 9, 562, 10.1038/nm863 Hardy, 1994, A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice, Cancer Res, 54, 5793 Gettinger, 2014, First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status, Proc Am Soc Clin Oncol, 32 Motzer, 2014, Nivolumab for metastatic renal cell carcinoma: results of a randomized phase ii trial, J Clin Oncol, 10.1200/jco.2014.32.15_suppl.5009 Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133 Aerts, 2013, Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer, Cancer research, 73, 2381, 10.1158/0008-5472.CAN-12-3932 Mahoney, 2014, Prognostic and predictive markers for the new immunotherapies, Oncology, 28, 39 Dorfman, 2006, Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma, Am J Surg Pathol, 30, 802, 10.1097/01.pas.0000209855.28282.ce Green, 2010, Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, Blood, 116, 3268, 10.1182/blood-2010-05-282780 Ansell, 2014, PD-1 is expressed on B-cells in Waldenstrom macroglobulinemia and promotes malignant cell viability and proliferation, Blood, 124, 10.1182/blood.V124.21.3015.3015 Wang, 2013, Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells, Haematologica, 98, 1458, 10.3324/haematol.2012.071340 Muenst, 2010, Diagnostic and prognostic utility of PD-1 in B cell lymphomas, Dis Markers, 29, 47, 10.1155/2010/404069 Chetaille, 2009, Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome, Blood, 113, 2765, 10.1182/blood-2008-07-168096 Shimauchi, 2007, Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma, Int J Cancer, 121, 2585, 10.1002/ijc.23042 Wilcox, 2009, B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders, Blood, 114, 2149, 10.1182/blood-2009-04-216671 Han, 2014, Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma, Oncol Lett, 8, 1461, 10.3892/ol.2014.2356 Chemnitz, 2007, RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma, Blood, 110, 3226, 10.1182/blood-2006-12-064360 Green, 2012, Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy, Clin Cancer Res, 18, 1611, 10.1158/1078-0432.CCR-11-1942 Brown, 2003, Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production, J Immunol, 170, 1257, 10.4049/jimmunol.170.3.1257 Yang, 2006, Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma, Blood, 107, 3639, 10.1182/blood-2005-08-3376 Dave, 2004, Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells, N Engl J Med, 351, 2159, 10.1056/NEJMoa041869 Carreras, 2009, High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma, J Clin Oncol, 27, 1470, 10.1200/JCO.2008.18.0513 Wahlin, 2010, A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1—positive, regulatory, cytotoxic, and helper T cells and macrophages, Clin Cancer Res, 16, 637, 10.1158/1078-0432.CCR-09-2487 Richendollar, 2011, Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma, Hum Pathol, 42, 552, 10.1016/j.humpath.2010.08.015 Takahashi, 2013, Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era, Eur J Haematol, 90, 286, 10.1111/ejh.12075 de Jong, 2011, The microenvironment in follicular lymphoma, Best Pract Res Clin Haematol, 24, 135, 10.1016/j.beha.2011.02.007 Delabie, 1993, The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines, Blood, 82, 2845, 10.1182/blood.V82.9.2845.2845 Nam-Cha, 2008, PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma, Am J Surg Pathol, 32, 1252, 10.1097/PAS.0b013e318165b0d6 Muenst, 2009, Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival, Hum Pathol, 40, 1715, 10.1016/j.humpath.2009.03.025 Greaves, 2013, Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells, Blood, 122, 2856, 10.1182/blood-2013-06-508044 Berger, 2008, Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies, Clin Cancer Res, 14, 3044, 10.1158/1078-0432.CCR-07-4079 Westin, 2014, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, Lancet Oncol, 15, 69, 10.1016/S1470-2045(13)70551-5 Armand, 2013, Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial, J Clin Oncol, 31, 4199, 10.1200/JCO.2012.48.3685 Lesokhin, 2014, Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies, Blood, 124, 10.1182/blood.V124.21.291.291 Ansell, 2015, PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 Moskowitz, 2014, PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013), Blood, 124, 10.1182/blood.V124.21.290.290 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Ribas, 2014, Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL), Proc Am Soc Clin Oncol, 32 Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624 Lipson, 2013, Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody, Clin Cancer Res, 19, 462, 10.1158/1078-0432.CCR-12-2625 Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369 Amin, 2014, Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC), Proc Am Soc Clin Oncol, 32 Rizvi, 2013, A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts), Proc Am Soc Clin Oncol, 31 Blazar, 2003, Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism, J Immunol, 171, 1272, 10.4049/jimmunol.171.3.1272 Koestner, 2011, PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells, Blood, 117, 1030, 10.1182/blood-2010-04-283119 Bashey, 2009, CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation, Blood, 113, 1581, 10.1182/blood-2008-07-168468